Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cocrystal Pharma Inc COCP

Healthcare
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function... see more

Recent & Breaking News (NDAQ:COCP)

Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones

GlobeNewswire November 15, 2021

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

GlobeNewswire November 8, 2021

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

GlobeNewswire November 1, 2021

Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021

GlobeNewswire October 21, 2021

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

GlobeNewswire October 14, 2021

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

GlobeNewswire October 6, 2021

Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

GlobeNewswire August 16, 2021

Cocrystal Pharma's SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

GlobeNewswire July 29, 2021

Cocrystal Joins Russell Microcap® Index

GlobeNewswire June 28, 2021

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

GlobeNewswire June 23, 2021

Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

GlobeNewswire June 14, 2021

Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online

GlobeNewswire June 9, 2021

Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

GlobeNewswire May 28, 2021

Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 17, 2021

Cocrystal Pharma Announces Closing of $40 Million Bought Deal

GlobeNewswire May 7, 2021

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

GlobeNewswire May 4, 2021

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

GlobeNewswire May 3, 2021

Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones

GlobeNewswire March 17, 2021

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

GlobeNewswire March 10, 2021